Phase 3 DREAM HF-1 read-out, page-277

I am not going to highlight cardiac progenitor cells for the simple reason that we do not know if they’ll be as affective as MSC’s for Chronic Heart Failure, and even if they were on par with MSC’s it would be another decade before they’ve gone through the safety and phase 1/2/3 trials required before approval would be granted.
MSB has something for CHF which could through regulatory approval starting next year, using Stem Cells which are even more potent than Ryoncil, and have had spectacular results at higher dosage in the animal and phase 1/2 studies, as well as passing all phase 3 DSMB meetings along the way.
Probably this week we shall see a solid Phase 3 result for this massive trial in CHF, showing mortality improvements as well.
I wouldn’t be surprised if a global partnership deal is announced in very short course for this CHF indication.